



\$~82

* **IN THE HIGH COURT OF DELHI AT NEW DELHI**

+ CS(COMM) 317/2026, I.As. 8033/2026, 8035/2026, 8037/2026
8039/2026

NOVO NORDISK A/S & ANR.Plaintiffs
Through: Mr. Hemant Singh, Ms. Mamta Jha,
Mr. Rishabh Paliwal, Mr. Shreyansh Gupta and
Mr. Sanchit Sharma, Advocates.

versus

DR REDDYS LABORATORIES LIMITEDDefendant
Through: Mr. Sandeep Sethi, Senior Advocate
with Mr. Ranjan Narula, Mr. Shakti Priyan Nair,
Mr. Parth Bajaj, Mr. Krisna Gambhir, Ms. Shreya
Sethi and Ms. Riya Kumar, Advocates.

CORAM:
HON'BLE MS. JUSTICE JYOTI SINGH

ORDER
30.03.2026

%

1. This suit is instituted by the Plaintiffs seeking decree of permanent injunction restraining the Defendant and all others acting on its behalf from using, manufacturing, selling, offering for sale, promoting and advertising, in any manner including online and/or directly or indirectly dealing, in pharmaceutical goods/services under the trademark OLYMVIQ and/or any other trademark identical/deceptively similar to Plaintiffs' trademark OZEMPIC, amounting to infringement of Plaintiffs' registered trademark and/or passing off and/or dilution, amongst other reliefs.

2. Mr. Sandeep Sethi, learned Senior Counsel for the Defendant, on instructions, submits that Defendant has agreed that:-


(a) Defendant shall forthwith stop any manufacture, sale, supply,



export, offer for sale, distribution, promotion, marketing, advertising and/or any other commercial use of any pharmaceutical product(s), either online or offline, under the trademark OLYMVIQ including its logo/label/packaging and/or any other trademark that may be identical or deceptively similar to Plaintiffs' trademark OZEMPIC and its logo/label/packaging;

(b) Defendant shall not in future manufacture, sell, supply, export, offer for sale, distribute, promote, market, advertise and/or put to commercial use any pharmaceutical product(s), either online or offline, using the trademark OLYMVIQ and/or its logo/label/packaging and/or any other trademark that may be identical or deceptively similar to Plaintiffs' trademark OZEMPIC and its logo/label/packaging;

(c) Defendant shall forthwith withdraw all pending trademark applications in respect of mark OLYMVIQ: Application bearing No. 7138396 dated 25.07.2025; Application bearing No. 7583858 dated

10.03.2026 for [ (device)]; Applications No. 7608750 and 7608751, both dated 23.03.2026 in Class 05; and

(d) Defendant shall forthwith transition to trademark 'OLYMRA' .

3. Mr. Sethi further submits that Defendant has an existing stock of injections, which have been manufactured and are ready for sale and subject to furnishing the relevant details on an affidavit, Defendant be permitted to sell the said stock within 30 days from today. For ready reference, the details indicated in the note handed over during the course of hearing are as follows:-



Manufactured and Ready Stock:

Product Description	Batch No.	Manufacturing Date	Expiry Date	Quantity
Semaglutide injection 2mg/1.5 ml Olymviq IN	7000592C	01-02-2026	31-01-2028	9217
Semaglutide injection 4mg/3ml Olymviq IN	7000588B	01-02-2026	31-01-2028	4035
Total				13252

4. Mr. Hemant Singh, learned counsel appearing for the Plaintiffs submits, on instructions, that Plaintiffs have no objection to Defendant transitioning to the proposed mark OLYMRA and thus the suit may be disposed of, subject to the Defendant giving the undertakings on an affidavit before this Court. He further submits that Plaintiffs do not press the relief of damages but actual costs incurred in filing and prosecuting the suit be awarded since Plaintiffs were compelled to approach the Court due to the impugned action of the Defendant.

5. Heard.

6. As noted above, Defendant agrees and undertakes to give up the impugned mark OLYMVIQ including its label/logo/packaging forthwith and not to use the said mark or any mark identical/deceptively similar to Plaintiffs' trademark OZEMPIC and/or its logo/label/packaging in future, in any manner whatsoever and transition to the proposed mark OLYMRA as also to withdraw the pending trademark applications. The undertaking is accepted and taken on record and needless to state shall bind the Defendant.

7. The only dispute remaining between the parties is with respect to sale of existing stock and costs of the suit. The product in question is used to treat type 2 diabetes mellitus and is a Schedule 'H' prescription drug. There is no dispute with respect to the quality of Defendant's product. Therefore,



in my view, it will be in public interest to permit the sale of the existing stock instead of directing its destruction. Accordingly, Defendant is permitted to sell the existing stock within a period of 30 days from today. Any stock remaining after the expiry of 30 days shall be donated to a Government hospital in the presence of authorized representative of the Plaintiffs.

8. Defendant shall file an affidavit within ten days from today undertaking that it shall forthwith stop manufacture, sale, supply, export, offer for sale, distribution, promotion, marketing, advertising and/or any other commercial use of any pharmaceutical product(s), through any mode whatsoever, under the trademark OLYMVIQ including its logo/label/packaging and/or any other trademark identical or deceptively similar to Plaintiffs' trademark OZEMPIC and/or its logo/label/packaging and shall not use the impugned mark or any mark identical or deceptively similar to trademark OZEMPIC and/or its logo/label/packaging in future and shall withdraw the pending trademark applications in respect of the impugned trademark. The affidavit shall also disclose the details of the existing stock of the injections, including batch number, manufacturing date, expiry date and quantity and include an undertaking that the existing stock will not be sold after expiry of 30 days from today.

9. In order to balance the equities, Plaintiffs are held entitled to 30% of the total amount claimed in the Bill of Costs, after deducting the amount sought towards court fees. Costs shall be paid by the Defendant within four weeks from today.

10. Suit stands decreed in terms of the settlement between the parties.

11. Registry is directed to draw up the decree sheet.

12. Suit stands disposed of along with pending applications.



13. Plaintiffs are held entitled to refund of entire court fees in accordance with the Court Fees Act, 1870.

JYOTI SINGH, J

MARCH 30, 2026
S.Sharma